Bms Ca031-002- A Phase 1/2 First-In-Human Study Of Bms-986258 Alone And In Combination With Nivolumab In Advanced Malignant Tumors
Posted Date: Sep 7, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine whether BMS-986258 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors. The primary endpoint of this study is to determine the incidence of AEs, SAEs, AEs meeting protocol-defined DLT criteria, AEs leading to discontinuation, and death.
Criteria:
To Be Eligible: Must Have Confirmed Diagnosis Of Hcc Localized To The Liver And Not Amenable To Curative Treatment, Adequately Controlled Blood Pressure With Or Without Antihypertensive Medications, Not Currently A Candidate For Liver Transplantation, No Gastric Bleeding Within The Last 6 Months, No Significant Cardiovascular Impairment Within 12 Months, No Serious Nonhealing Wound, Ulcer, Or Bone Fracture
Keywords:
Advanced Malignant Tumors, Cancer, Phase 1
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com